medications

The impact of the COVID-19 pandemic on cardiovascular disease prevention and management

section { background: white; color: black; border-radius: 1em; padding: 1em; left: 50% } #inner { display: inline-block; display: flex; align-items: center; justify-content: center } Twitter thread summarising key results

The adverse impact of COVID-19 pandemic on cardiovascular disease prevention and management in England, Scotland and Wales: A population-scale descriptive analysis of trends in medication data

❗ Now published in Nature Medicine Caroline E Dale, Rohan Takhar, Raymond Carragher, Michalis Katsoulis, Fatemeh Torabi, Stephen Duffield, Seamus Kent, Tanja Mueller, Amanj Kurdi, Stuart McTaggart, Hoda Abbasizanjani, Sam Hollings, Andrew Scourfield, Ronan Lyons, Rowena Griffiths, Jane Lyons, Gareth Davies, Daniel Harris, Alex Handy, Mehrdad Alizadeh Mizani, Chris Tomlinson, Johan Thygesen, Mark Ashworth, Spiros Denaxas, Amitava Banerjee, Jonathan Sterne, Paul Brown, Ian Bullard, Rouven Priedon, Mamas A Mamas, Ann Slee, Paula Lorgelly, Munir Pirmohamed, Kamlesh Khunti, Andrew Morris, Cathie Sudlow, Ashley Akbari, Marion Bennie, Naveed Sattar, Reecha Sofat, CVD-COVID-UK Consortium (2023).